Guangdong Tai'an Tang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, without false records, misleading statements, or significant omissions.
On April 29, 2024, the Company held the 11th meeting of the 6th Board of Directors, where it reviewed and approved the proposal regarding uncovered losses reaching one-third of the total paid-in capital. The specific situation is announced as follows:
1. Overview
According to the audit by Sichuan Huaxin (Group) Accounting Firm (Special General Partnership), the Company achieved a net profit attributable to shareholders of the listed company of -CNY 2,210,086,625.22 for the fiscal year 2023. The amount of uncovered losses is -CNY 3,372,734,897.09, while the paid-in capital is CNY 766,773,200.00. The uncovered losses exceed one-third of the total paid-in capital. According to the Company Law, Articles of Association, and other relevant regulations, this matter needs to be submitted to the shareholders' meeting for deliberation.